Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7756117 | 0.88 | CYP2C9 (0.54) | MAPTCYP2C9TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4436251 | 0.85 | CYP1A2 (0.52) | MAPTSMN1; SMN2ALDH1A1KMT2AMAPK14 | |
| SCHEMBL7187475 | 0.83 | TDP1 (0.61) | MAPTSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL28255681 | 0.83 | SLC2A1 (0.63) | SLC2A1MAPTCYP2C9TSHREGFR | |
| SCHEMBL4168384 | 0.81 | ALDH1A1 (0.56) | MAPTSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL7192635 | 0.81 | SLC1A3 (0.61) | MAPTSMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL6099629 | 0.81 | POLB (0.56) | SLC2A1EGFRSMN1; SMN2LMNAHTT | |
| SCHEMBL22219121 | 0.81 | SMN1; SMN2 (0.47) | MAPTCYP2C9SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL7188387 | 0.80 | MAPT (0.57) | MAPTSMN1; SMN2ALDH1A1KMT2ALMNA | |
| SCHEMBL26571944 | 0.80 | TDP1 (0.61) | SLC2A1MAPTTSHREGFRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109201-B2 | Piperazine derivatives, their preparation and uses in therapy | SMITHKLINE BEECHAM PLC (GB) | 2006-09-19 | — | — | US | disclosed |
| EP-1368337-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1368337-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002074764-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | NR3C2, NR2C2, NR3C1 | SLC2A1 1882/4885MAPT 3454/4885CYP2C9 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.